Overview

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Status:
Not yet recruiting
Trial end date:
2026-10-15
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).
Phase:
Phase 4
Details
Lead Sponsor:
Amgen
Treatments:
Denosumab